33/23. Elrantamab-bcmm- (ELREXFIO)- (Aug 2023)- to treat adults with relapsed refractory multiple myloma who have received at least four prior therapy
Drug Name:
33/23. Elrantamab-bcmm- (ELREXFIO)- (Aug 2023)- to treat adults with relapsed refractory multiple myloma who have received at least four prior therapy
List Of Brands:
Indication Type Description:
Indication:
BRIEF SUMMARY
ELRANTAMAB-(Aug 2023)
Indcn - To treat adults with relapsed refractory ultiple myeloma
Dosage-
ADR-
CI-
DI-
Pat infor
==================================================================
U.S. APPROVED DRUGS DURING 2023
Serial No 33
Name- ELREXFIO
Acive Ingredient - Elrantamab-bcmm
Pharmacological clssificiation- To treat adults with relapsed refractory multiple myeloma who have received at least four prior therapy
Date of Approval- 8/4/2023
